Plate Quotes
December 9, Shenwan Pharmaceutical and Biological
Plate Quotes
December 9, Shenwan Pharmaceutical and Biological Index closed at 11392.18 points, down 1.38% on the day. The overall turnover of the plate 64.8 billion yuan, the average turnover rate of 1.16%. Breakdown of the plate, pharmaceutical business fell 1.24%, medical services fell 1.45%, biological products fell 1.15%, chemical pharmaceuticals fell 1.69%, Chinese medicine fell 0.32%, medical equipment fell 1.87%.
Industry News
- According to WHO and Hopkins University, as of 18:00 Beijing time on December 9, the cumulative number of new coronary pneumonia cases diagnosed overseas is 68587933 cases, the cumulative number of cured cases is 47326181 cases, and the cumulative number of deaths is 1,555,956 cases. Among them, 534,621 cases were newly diagnosed on the same day, 421,177 cases were newly cured, and 10,729 cases were newly died. The top five countries in terms of cumulative number of confirmed cases were the United States (15,591,709 cases), India (97,358,550 cases), Brazil (6,674,999 cases), Russia (2,518,551 cases) and France (2,363,197 cases). Domestically, according to the information disclosed on the website of the National Health Commission, on December 8, there were 15 new confirmed cases in the country, of which 11 cases were imported from abroad (6 cases in Shanghai, 2 cases in Guangdong, 1 case in Jiangsu, 1 case in Guangxi, and 1 case in Sichuan), and 4 local cases (all in Sichuan).
- December 9, the Internet rumor "on the fourth batch of national organization drug centralized purchasing varieties range of relevant procurement data notice" shows that the fourth batch of collective purchasing will be officially launched on December 12 to report the amount of *** involving 44 varieties of 90 specifications. However, the document has not been officially announced. The staff of the Shanghai Pharmaceutical Institute said that everything is subject to the official release of information on the Shanghai Sunshine Pharmaceutical Purchasing Network.
- In the morning of December 9, Bazis announced that the marketing application for the treatment of relapsed or refractory (R/R) precursor B-cell acute lymphoblastic leukemia (ALL) in adults has been approved by China's National Medicines and Products Administration (NMPA) for the treatment of BLINCYTO (berlinatumab for injection), which was developed by Amgen, and was approved by the Chinese NMPA under a global oncology strategic partnership reached earlier this year. The application was approved by the NMPA in China, and BaxiSinZhou was granted authorization to market ALL in China under a strategic global oncology collaboration concluded earlier this year.
- On December 9, Watson Biologicals replied to the SZSE's letter of concern and the Yunnan Securities Regulatory Bureau's letter of inquiry, denying that it had sold Shanghai Zerun at a low price and emphasizing that it did not harm the interests of the listed company and small and medium-sized investors.
- On the evening of December 8, Yanan Bikang announced that Shaanxi Bikang, a wholly-owned subsidiary of the company, intends to transfer 100% equity interest in Wuhan Wujing Pharmaceutical Company Limited, a wholly-owned subsidiary of the company, to Guardian Capital.
- On the evening of December 8, Boten announced that it intends to use its own funds of RMB 4 million to set up a joint venture with Mr. Ju Nianfeng, one of the controlling shareholders and de facto controller, as well as Mr. Bo Yinghui and Mr. Du Jingang***, dedicated to combining the needs of China's market and exploring the introduction of overseas innovative drugs to provide services to enrich the pipeline of innovative drug research and development projects of China's pharmaceutical companies.
- On the evening of December 8, Matilda Bio announced that the company will invest in the establishment of a wholly-owned subsidiary, Matilda Medical, with its own funds. The registered capital of Mind Medical is 5 million yuan, and Mind Bio accounts for 100% of its total equity.
- On the evening of December 8, Kemper Bio announced that Ms. Wang Jianyu, the company's de facto controller, director, and executive vice president, increased her holdings of the company's shares by 170,000 shares, accounting for 0.07% of the company's total share capital, by means of block trading with her own funds on December 8, 2020.
Stocks up and down
December 9, Shenwan pharmaceutical and biological plate 357 traded stocks *** 47 rose. Among them, the tour of the sea medical rose 10% that day, the top of the rate of increase. State medicine shares, Pientzehuang and other top gainers. In addition, Hao Hai Shengke, Nanjing Xinbai, the old people, Jianzhijia, etc. fell more.
The above stocks in recent weeks news also include:
December 8 evening, Nanjing New Century received the SSE on its to related parties to increase the capital of the relevant matters of the inquiry letter. Which requires Nanjing Xinbai to supplement the disclosure of Xuzhou Sanjiu medical main financial data in the recent year and a period of time, the short-term debt to wholly-owned subsidiaries and sold whether the interests of listed companies.
---------------------------------------------------------------------------
The Financial Sector Pharmaceutical and Biological Studio is a new capital market + pharmaceutical and biological industry media platform created by the Financial Sector Listed Company Center. It is dedicated to connecting pharmaceutical and biological enterprises with the capital market and delivering scientific research and business value.
Contact Us: xiaofeng.he@jrj.com.cn